Stuart Essig worked closely with Towerbrook in identifying and partnering with this company. TriMedx started as a hospital clinical engineering department focusing on reducing expenses, optimizing service and enhancing the patient experience through innovative medical equipment management programs. Today, TriMedx is recognized around the globe as a leader in healthcare technology management.
Prettybrook co-invested with Wellington Partners in this company which has developed a unique, minimally-invasive implantable device designed to provide long-term reflux control by restoring normal esophageal function through low-energy personalized neurostimulation.
Prettybrook co-invested with TPG Capital in this company. Beaver-Visitec International is focused on developing and manufacturing new, innovative and reliable products for a variety of ophthalmic and specialty microsurgical procedures.
Prettybrook made a direct investment, along with Wellington Partners, in this early stage company which is developing a therapy combining a spinal cord implant with robot-assisted training with an aim to accelerate and augment functional recovery of people with spinal cord injury.
Prettybrook co-invested with Waters Street in this company. ELAP works with companies to design self-insured health plans and manage their medical claims. It conducts detailed audits on their medical bills and reprices them based on an analysis of the medical providers' actual costs and Medicare rates.
Prettybrook led a $4 million preferred equity investment. Erin Enright serves as a Director of this publicly traded leading manufacturer and distributor of physical therapy products.
Stuart Essig is Chairman of the Board of this leader in the sports medicine market, having participated in the leveraged buyout of the business with Water Street Capital Partners.
Prettybrook made a direct investment in this emerging player in Health Savings Account management. Recently completed IPO.
Prettybrook made a direct investment in this tissue phenomics company. Recently was sold to AstraZeneca.
Prettybrook made a direct investment in this manufacturer of time-temperature indicators for sensitive vaccines, pharmaceuticals and medical devices.
Prettybrook made a direct investment in this London based provider of staffing, complex care services and administrative outsourcing for clients in the healthcare sector
Prettybrook made a direct investment in this emerging player in home dialysis.
Prettybrook has a direct investment in this medical education company.
Prettybrook has a direct investment in this emerging player in urologic devices.
Prettybrook participated in the leveraged acquisition of this disposable hearing aid manufacturer and Erin Enright acted as a board observer.
Prettybrook is a Series A investor in this emerging leader in spinal cord stimulation.
Stuart Essig serves as Chairman of the Board of Directors of this market leader in regenerative medicine. He previously served as Chief Executive Officer for 14 years.
Stuart Essig served at Goldman Sachs for ten years as a senior merger and acquisitions advisor to medical technology, pharmaceutical and biotechnology clients.
From 1993 to 2003, Erin Enright served at Citigroup, most recently as a Managing Director in its Equity Capital Markets group. While at Citigroup, Ms. Enright was Chairperson of the firm’s Institutional Investors’ Committee, responsible for screening and approving the firm’s participation in equity underwritings and a member of the Citigroup Global Equity Commitment Committee, responsible for reviewing and approving the firm’s underwritings.
Erin Enright acquired this manufacturer of bone-marrow needles in 2004 and has served as President of the company. The company was sold in 2013.
Erin Enright acquired this manufacturer of disposable products for the spine market in 2011 and has served as President of the company. The Company was sold in 2013.
Erin Enright participated in the IPO of this company as CFO in 2006, raising $100 million. The Company consummated the acquisition of InfuSystem Holdings in 2007.
Stuart Essig has served as a St. Jude Medical director since 1999.
Stuart Essig served as a Director of this Fortune 500 orthopedics company from 2005 to 2008.
Stuart Essig has served as a Director of this medical products distribution company since 2013
Stuart Essig serves as a Director and Chair of the nominating and governance committee of this spinal products company.
Stuart Essig serves as a Senior Advisor to this private equity firm. Towerbrook has over $6 billion under management.
Stuart Essig serves as a Senior Advisor to this private equity firm, which has over $2 billion under management.
Stuart Essig serves as an Executive in Residence for this market leading venture capital firm.
Stuart Essig serves as a Venture Partner for this Munich based pan-European venture capital firm focused on healthcare.
Stuart Essig served as Director, Treasurer and on the Executive Committee of the Medical Device industry Manufacturers Organization.
Erin Enright and Stuart Essig were founding members of this Princeton based healthcare information technology accelerator. Ms. Enright serves on the Board of Directors.
Erin Enright served as a Director and on the audit committee of this publicly traded leading manufacturer and distributor of dental lasers.
Stuart Essig served as a Director of this manufacturer of disposable anesthesia devices from 1998 to 2002.